Figures
Abstract
Leptin improves insulin sensitivity in skeletal muscle. Our goal was to determine whether proteins controlling GLUT4 traffic are altered by leptin deficiency and in vivo leptin administration in skeletal muscle of wild type and ob/ob mice. Leptin-deficient ob/ob mice were divided in three groups: control, leptin-treated (1 mg/kg/d) and leptin pair-fed ob/ob mice. Microarray analysis revealed that 1,546 and 1,127 genes were regulated by leptin deficiency and leptin treatment, respectively. Among these, we identified 24 genes involved in intracellular vesicle-mediated transport in ob/ob mice. TBC1 domain family, member 1 (Tbc1d1), a negative regulator of GLUT4 translocation, was up-regulated (P = 0.001) in ob/ob mice as compared to wild types. Importantly, leptin treatment reduced the transcript levels of Tbc1d1 (P<0.001) and Tbc1d4 (P = 0.004) in the leptin-treated ob/ob as compared to pair-fed ob/ob animals. In addition, phosphorylation levels of TBC1D1 and TBC1D4 were enhanced in leptin-treated ob/ob as compared to control ob/ob (P = 0.015 and P = 0.023, respectively) and pair-fed ob/ob (P = 0.036 and P = 0.034, respectively) mice. Despite similar GLUT4 protein expression in wild type and ob/ob groups a different immunolocalization of this protein was evidenced in muscle sections. Leptin treatment increased GLUT4 immunoreactivity in gastrocnemius and extensor digitorum longus sections of leptin-treated ob/ob mice. Moreover, GLUT4 protein detected in immunoprecipitates from TBC1D4 was reduced by leptin replacement compared to control ob/ob (P = 0.013) and pair-fed ob/ob (P = 0.037) mice. Our findings suggest that leptin enhances the intracellular GLUT4 transport in skeletal muscle of ob/ob animals by reducing the expression and activity of the negative regulators of GLUT4 traffic TBC1D1 and TBC1D4.
Citation: Sáinz N, Rodríguez A, Catalán V, Becerril S, Ramírez B, Lancha A, et al. (2012) Leptin Reduces the Expression and Increases the Phosphorylation of the Negative Regulators of GLUT4 Traffic TBC1D1 and TBC1D4 in Muscle of ob/ob Mice. PLoS ONE 7(1): e29389. https://doi.org/10.1371/journal.pone.0029389
Editor: Giorgio Sesti, Universita Magna-Graecia di Catanzaro, Italy
Received: May 23, 2011; Accepted: November 28, 2011; Published: January 9, 2012
Copyright: © 2012 Sáinz et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by a fellowship from the Department of Industry of the Gobierno de Navarra of Spain to NS and grants from the Fundación Mutua Madrileña to GF; from the Instituto de Salud Carlos III, Fondo de Investigación Sanitaria (FIS) del Ministerio de Sanidad y Consumo to GF and JG-A; and from the Department of Health of the Gobierno de Navarra of Spain to GF and JG-A. CIBER de Fisiopatología de la Obesidad y Nutrición (CIBERobn) is an initiative of the Instituto de Salud Carlos III, Spain. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Introduction
Skeletal muscle constitutes the tissue with the highest insulin-stimulated glucose uptake. Of several potential facilitative glucose transporters (GLUTs) the GLUT4 isoform is primarily expressed in insulin-responsive tissues, including skeletal muscle and adipose tissue. Insulin stimulates the traffic of GLUT4-containing vesicles to the cell surface and induces their fusion to the plasma membrane [1]. GLUT4 is a continuosly recycling membrane protein with defects in the translocation of GLUT4 from intracellular depots to the plasma membrane being associated with insulin resistance in muscle cells and adipocytes [2].
A key signal transduction pathway for GLUT4 translocation is the Akt-induced phosphorylation of Rab GTPase-activating protein (GAP) AS160, also known as TBC1 domain family, member 4 (TBC1D4) [3]. The phosphorylation of TBC1D4 suppresses its GAP activity, thereby triggering the machinery for the docking of GLUT4 vesicles to the plasma membrane [4]. More recently, several groups have characterized a paralog of TBC1D4 important for regulating body weight and linked to obesity, known as TBC1D1, that is predominantly expressed in skeletal muscle [5], [6]. Both TBC1D4 and TBC1D1 have been defined as negative regulators of GLUT4 vesicle translocation to the plasma membrane [7]. On the other hand, the fusion of GLUT4-containing vesicles with the plasma membrane in muscle and fat cells is mediated by SNAP-associated receptor (SNARE) proteins, such as synaptosomal-associated protein 23 (SNAP23), syntaxin 4, and vesicle-associated membrane protein 2 (VAMP2). This process can be negatively regulated by Munc18c (mammalian homologue of Unc-18) and syntaxin 4-binding protein (Stxbp4, also known as Synip) [8], [9].
Leptin, the product of the ob gene, is an adipose-derived hormone that acts as an afferent signal in a negative-feedback loop inhibiting the appetite and regulating adiposity [10], [11]. In addition to its central function as a satiety factor, many peripheral effects of leptin on metabolism have been described [12], [13]. Leptin increases insulin sensitivity in normal and diabetic murine models [14], [15]. The hormone increases the basal and insulin-induced glucose uptake in isolated muscles of rodents as well as in cultured cells in a PI3-kinase (PI3K)-dependent manner [16], [17]. Furthermore, activation of AMP-activated protein kinase (AMPK) stimulates the gene expression of GLUT4 [18] and promotes its translocation to the sarcolemma [19] with leptin activating AMPK in skeletal muscle [20], [21].
In this study, we show for the first time, the in vivo participation of leptin in the regulation of gene expression and phosphorylation of TBC1D1 and TBC1D4, key molecules in the traffic of GLUT4 in skeletal muscle of leptin-deficient ob/ob mice.
Methods
Animals and Treatments
Ten-week-old male obese ob/ob mice (Lepob/Lepob, C57BL/6J) (n = 18) and their lean wild type littermate controls (n = 6) (Harlan, Barcelona, Spain), were housed in a room with controlled temperature (22±2°C) and a 12∶12 light-dark cycle. The ob/ob mice were divided in control, leptin-treated and pair-fed groups (n = 6 per group). The wild type as well as the control ob/ob and pair-fed ob/ob groups received vehicle (PBS), while leptin-treated ob/ob mice were intraperitoneally administered with leptin (1 mg/kg/d) (Bachem, Bubendorf, Switzerland) twice daily at 08:00 am and 08:00 pm for 28 days. Wild type, control ob/ob and leptin-treated ob/ob groups were provided with water and food ad libitum with a standard rodent chow (2014S Teklad, Harlan), while daily food intake of the pair-fed ob/ob group was matched to the amount eaten by the leptin-treated ob/ob group the day before to discriminate the inhibitory effect of leptin on appetite. Mice were sacrificed on the 28th day of treatment by CO2 inhalation 20 h after the last PBS or leptin administration (in order to avoid picking up effects reflecting an acute response) and after 8 h of fasting. Fasting blood and the gastrocnemius, extensor digitorum longus (EDL) and soleus muscles in fasted-basal conditions were obtained for biochemical and molecular analyses. The gastrocnemius muscle from one hindleg was removed for mRNA and protein extraction. Triacylglycerol (TG) content in gastrocnemius muscle was measured using a commercially available method (Wako, Osaka, Japan). The contralateral hindleg gastrocnemius, as well as the EDL and the soleus muscles were formalin-fixed for immunohistochemical analyses All experimental procedures conformed to the European Guidelines for the Care and Use of Laboratory Animals (directive 86/609). The protocol was approved by the Ethical Committee for Animal Experimentation of the University of Navarra (080/05).
Blood Analyses
Serum glucose was analyzed using a sensitive-automatic glucose sensor (Ascensia Elite, Bayer, Barcelona, Spain). Serum TG concentrations were spectrophotometrically determined using a commercial kit (Infinity, Thermo Electron, Melbourne, Australia). Free fatty acids (FFA) concentrations were measured using the colorimetric NEFA C kit (Wako), while glycerol was evaluated by enzymatic methods [22]. ELISA kits were used to assess insulin, leptin (Crystal Chem Inc., Chicago, IL, USA) and adiponectin (BioVendor Laboratory Medicine, Inc., Modrice, Czech Republic) concentrations. Insulin resistance was estimated using the HOMA index (fasting insulin [µU/mL]×fasting glucose [mmol/L]/22.5). Insulin sensitivity was determined using the QUICKI index (1/[log(fasting insulin µU/mL)+log(fasting glucose mg/dL)].
Microarray
Total RNA was extracted from gastrocnemius muscle samples (20–30 mg) of wild type, control ob/ob and leptin-treated ob/ob mice using TRIzol™ reagent (Invitrogen, Barcelona, Spain) as previously described [21]. Gene expression analyses were conducted using the Agilent Whole Mouse Genome array (G4121B, Agilent Technologies, Santa Clara, CA, USA), containing more than 41,000 mouse transcripts. Briefly, 1 µg of total RNA from each sample was amino-allyl labelled and amplified using the Amino Allyl MessageAmp II aRNA Amplification Kit (Ambion, Austin, TX, USA). Amplified aRNA was fluorescently labelled using Cy3/Cy5 (Amersham Biosciences, Buckinghamshire, UK) and hybridized to Agilent oligomicroarrays. Two hybridizations with fluor reversal (Dye swap) were performed for each sample (n = 5 per group). Microarray slides were scanned (Gene Pix 4100A scanner, Axon Instruments, Union City, CA, USA) and the images quantified with the software GenePiX Pro 6.0. Gene expression data were analyzed using the GeneSpring GX software v. 7.3.1 (Agilent Technologies). Clustering was accomplished with the Gene and Condition Tree algorithms. Gene Ontology groupings (http://babelomics.bioinfo.cipf.es) and the KEGG website (http://www.genome.ad.jp/kegg/pathway) were used in conjunction with GeneSpring (http://www.agilent.com/chem/genespring) to identify pathways and functional groups of genes modified by leptin deficiency and administration. All microarray data reported are described in accordance with MIAME guidelines. More information regarding the microarray experiments can be found at the EMBL-European Bioinformatics Institute (http://www.ebi.ac.uk/aerep/login. ArrayExpress accession number: E-MEXP-1831).
Real-Time PCR
For first strand cDNA synthesis, constant amounts of total RNA isolated from the gastrocnemius muscle of wild type, control ob/ob, pair-fed ob/ob and leptin-treated ob/ob were reverse-transcribed as previously described [21]. Specific primers and probes to each target gene were designed using the software Primer Express 2.0 (Applied Biosystems, Foster City, CA, USA) (Table 1). The cDNA was amplified using the TaqMan® Universal PCR Master Mix (Applied Biosystems) and the transcript levels for Tbc1d1, Tbc1d4 and Slc2a4 (Glut4) were quantified by Real-Time PCR (7300 Real-Time PCR System, Applied Biosystems). All results were normalized to the levels of 18S rRNA (Applied Biosystems) and relative quantification was calculated using the ΔΔCt formula.
Preparation of Tissue Lysates
Gastrocnemius, EDL and soleus muscles (10–70 mg) were homogenized in ice-cold lysis buffer (10 mmol/L EDTA·2H2O, 50 mmol/L NaCl; 1% Triton X-100, 2 mmol/L phenylmethylsulfonyl fluoride) supplemented with a protease inhibitor cocktail (Complete™ Mini-EDTA free, Roche Molecular Biochemicals, Mannheim, Germany) and phosphate inhibitors (50 mmol/L sodium pyrophosphate, 0.1 mol/L NaF, 10 mmol/L Na3VO4). Lysates were centrifuged (16,000 g, 4°C) for 25 min and protein concentrations determined in the supernatants (Bio-Rad Laboratories, Inc., Hercules, CA, USA).
Immunoprecipitation
TBC1D1 and TBC1D4 proteins were immunoprecipitated from gastrocnemius lysates (250 µg of total protein) using rabbit polyclonal anti-TBC1D1 and TBC1D4 antibodies (Cell Signaling, Inc., Danvers, MA, USA) overnight at 4°C, followed by incubation with protein A-agarose beads (Roche) for 2 h at 4°C. The mixture was centrifuged (16,000 g, 4°C) for 15 s and supernatants were removed. Bead-antibody-protein complexes were washed in lysis buffer and proteins were eluted from protein A-agarose beads by boiling in Laemmli buffer.
Immunoblots
Muscle lysates (30 µg) and immunoprecipitates were run out in 10% SDS-PAGE, subsequently transferred to nitrocellulose membranes (Bio-Rad Laboratories) and blocked in Tris-buffered saline (10 mmol/L Tris-HCl, 150 mmol/L NaCl, pH 8.00) with 0,05% Tween 20 (TBS-T) containing 5% BSA (Sigma, St. Louis, MO, USA) for 2 h at room temperature (RT). Blocked membranes of lysates and immunoprecipitates were probed with the primary antibodies rabbit polyclonal anti-GLUT4 (Abcam, Cambridge, UK) and rabbit polyclonal anti-phospho-Akt-substrate (PAS) (Cell Signaling), in blocking buffer overnight at 4°C. The antigen-antibody complexes were visualized using horseradish peroxidase (HRP)-conjugated anti-rabbit, anti-mouse (Amersham Biosciences) (Abcam) IgG antibodies in TBS-T containing 5% non-fat dry milk for 1 h at RT and the enhanced chemiluminescence ECL Plus detection system (Amersham Biosciences). Membranes of immunoprecipitates probed with PAS and GLUT4 antibodies were stripped and re-probed with the corresponding total antibody rabbit polyclonal anti-TBC1D1 and anti-TBC1D4 (Cell Signaling). The signals from PAS-TBC1D1, PAS-TBC1D4, GLUT4-TBC1D1 and GLUT4-TBC1D4 were related to total TBC1D1 and TBC1D4 in the immunoprecipitate sample. Mouse monoclonal anti-β-actin (Sigma) was used for normalization of GLUT4 density values from total protein lysates of muscle. Bands were analyzed by densitometric analysis using the Gel Doc-Quantity One 4.5.0., Bio-Rad).
Immunohistochemistry
Sections (5 µm) of formalin-fixed paraffin-embedded muscles (gastrocnemius, EDL and soleus) were dewaxed in xylene and rehydrated in decreasing concentrations of ethanol. Slides were blocked with 5% normal goat serum (Sigma) diluted in TBS (0.05 mol/L Tris-HCl buffer, 0.5 mol/L NaCl, pH 7.36) for 30 min at RT followed by incubation with the rabbit polyclonal anti-GLUT4 antibody (Abcam) in TBS with 5% normal goat serum overnight at 4°C. After washing, the endogen peroxidase activity was quenched using 3% H2O2 (Sigma) in distilled water for 20 min at RT. Sections were incubated with goat anti-rabbit EnVision-HRP conjugate (Dako Corporation, Hamburg, Germany) for 20 min at RT after subsequent washing. The immunocomplexes were visualized by adding 0.03% 3,3-diaminobenzidine (Dako) as developing system. Negative control slides with omission of the primary antibodies were included. The reaction was stopped and contrasted with Harris' hematoxylin solution (Sigma). Sections were dehydrated and mounted in DePeX (Panreac, Barcelona, Spain).
Statistical Analyses
All statistical analyses were performed using SPSS 15.0 (SPSS, Chicago, IL, USA). Differences between groups were assessed by one-way ANOVA followed by LSD tests. As previously outlined, Gene Ontology groupings were used to identify pathways significantly affected by leptin deficiency and administration. Statistical comparisons for microarray data to identify differentially expressed genes across different groups were performed using one-way ANOVA and Student's t-tests as appropriate. Data are expressed as mean±SEM. Statistical significance was defined as P<0.05.
Results
Metabolic profile of wild type and ob/ob mice
As expected, leptin treatment corrected the obese and diabetic phenotype of ob/ob mice (Table 2). Body weight of leptin-treated ob/ob animals was reduced by leptin treatment as compared to the control ob/ob (P<0.0001) and pair-fed ob/ob (P<0.0001) groups. Leptin administration normalized both glucose (P = 0.961) and insulin (P = 0.985) concentrations in leptin-treated ob/ob mice compared to wild types. Moreover, leptin increased insulin sensitivity in peripheral tissues, as evidenced by the higher QUICKI index in the leptin-treated ob/ob mice than in the control ob/ob (P<0.0001) and pair-fed ob/ob (P = 0.007) groups, with no statistical differences between wild type and leptin-treated ob/ob animals.
Leptin alters gene expression of key regulators of GLUT4 traffic
Differential gene expression profiles in the gastrocnemius muscle of wild type, control ob/ob and leptin-treated ob/ob groups were compared by microarray analysis. Leptin repressed 736 genes that were up-regulated in the control ob/ob and increased the transcript levels of 846 down-regulated genes. As shown in Table 3, functional analysis of the genes revealed that a number of these are involved in the insulin signaling pathway and glucose metabolism processes.
To further characterize the actions of leptin on intracellular GLUT4 traffic, we then decided to focus on the set of genes encoding proteins involved in the vesicle-mediated transport process. Table 4 shows that 24 genes encoding proteins involved in the vesicle-mediated transport between the plasma membrane and the intracellular reservoirs were modified by leptin in ob/ob mice. Among them, leptin increased gene expression of the glucose transporters Slc2a3 (Glut3) and Slc2a12 (Glut12), while it decreased the mRNA levels of the inhibitors of GLUT4 translocation Tbc1d1 and Tbc1d4, as compared to control ob/ob mice. On the contrary, the expression of the genes involved in the fusion to the membrane of GLUT4-containing vesicles, Vamp2, Vamp4, Vamp5 and Vamp8, Stxbp4, Stx8 and Sybl1, was up-regulated by leptin administration in ob/ob animals.
Expression of GLUT4 in skeletal muscle of wild type and ob/ob mice
No differences for GLUT4 mRNA levels GLUT4 in homogenates of gatrocnemius and soleus muscles between wild type and ob/ob groups were found. However, gene expression levels of GLUT4 were reduced in EDL of control ob/ob (P = 0.007) as compared with wild types, while no effect of leptin administration was detected (Figure 1A). Protein abundance of GLUT4 was not affected by leptin deficiency and leptin administration in gastrocnemius, EDL and soleus muscles of ob/ob mice (Figure 1B). To characterize the involvement of leptin on GLUT4 translocation to the plasma membrane an immunohistochemical analysis for the GLUT4 protein in muscle sections of the diverse groups was performed. As shown in Figure 2, a different pattern of GLUT4 immunostaining was detected between muscle sections of wild type and ob/ob groups. In wild types, GLUT4 staining was almost exclusively relegated to some gastrocnemius fibers, with typical intracellularly scattered punctate and non-continuous staining observed in the cell surface. In contrast, in leptin-deficient mice (control ob/ob and pair-fed ob/ob groups) the staining pattern of GLUT4 was uniformly distributed among almost all the gastrocnemius fibers. Interestingly, leptin increased immunoreactivity of GLUT4 in some gastrocnemius fiber sections of the leptin-treated ob/ob group as compared to control ob/ob and pair-fed ob/ob mice, consistent with the GLUT4 staining pattern of wild types. In EDL sections, GLUT4 immunostaining was not altered by leptin deficiency but leptin treatment markedly enhanced immunoreactivity for GLUT4 in muscle sections of leptin-treated ob/ob mice. In contrast, a lower immunostaining for GLUT4 was observed in the soleus sections of control ob/ob as compared to wild types and no effect of leptin replacement was detected.
A: Real-Time PCR analysis of Glut4 mRNA in the gastrocnemius, extensor digitorum longus (EDL) and soleus muscles of wild type, control ob/ob, pair-fed ob/ob and leptin-treated ob/ob mice (n = 6 per group). B: Representative Western blot analysis of GLUT4 of the gastrocnemius, EDL and soleus muscles of wild type, control ob/ob, pair-fed ob/ob and leptin-treated ob/ob mice. β-actin was used as a loading control (n = 6 per group). Values are presented as means±SEM. * P<0.05 by one-way ANOVA followed by LSD tests.
Representative images of GLUT4 immunostaining in sections of the gastrocnemius, extensor digitorum longus (EDL) and soleus of wild type (WT), control ob/ob (OB), pair-fed ob/ob (PF) and leptin-treated ob/ob (LE) mice. Larger-magnification images within black frames of immunohistochemical staining for GLUT4 in gastrocnemius, EDL and soleus sections of leptin-treated ob/ob mice are shown. Arrows indicate punctuate distribution of GLUT4 vesicles in plasma membrane and cytosol of muscle sections. Scale bars = 50 µm.
Leptin reduces gene expression levels of Tbc1d1 and Tbc1d4 in skeletal muscle of ob/ob mice
Consistently with microarray data, real-time PCR analyses demonstrated that Tbc1d1 mRNA levels were up-regulated in gastrocnemius of control ob/ob mice as compared to wild types (P = 0.0012). A trend towards higher transcript levels of Tbc1d4 between control ob/ob and wild type groups was detected. However, no significant differences were observed (P = 0.066). Importantly, leptin replacement reduced the expression of Tbc1d1 (P = 0.0005) and Tbc1d4 (P = 0.004) in gastrocnemius of leptin-treated ob/ob as compared to control ob/ob animals (Figure 3A–B). In addition, higher (P = 0.05) transcript levels of Tbc1d1 were detected in EDL of control ob/ob as compared to wild types. No effect of either leptin deficiency or leptin administration was detected for mRNA levels of Tbc1d1 and Tbc1d4 in the soleus muscle (Figure 3A–B).
Real-Time PCR analysis of Tbc1d1 (A) and Tbc1d4 (B) mRNA in the gastrocnemius, extensor digitorum longus (EDL) and soleus muscles of wild type, control ob/ob, pair-fed ob/ob and leptin-treated ob/ob mice (n = 6 per group). Values are presented as means±SEM. * P<0.05, ** P<0.01 and *** P<0.001 by one-way ANOVA followed by LSD tests.
Leptin increases the phosphorylation of TBC1D1 and TBC1D4 in ob/ob mice
The phosphorylation status of TBC1D1 and TBC1D4 in the gastrocnemius of wild type and ob/ob mice was determined using the PAS antibody. Figure 4A evidences multiple PAS bands in all the groups and reveals a general increase of the PAS signal in the leptin-treated ob/ob group. Among the PAS bands detected in the anti-PAS immunoblot, a band migrating at approximately the 150-kDa location was included. Moreover, this band was reduced in control ob/ob as compared to wild type mice and increased after leptin treatment. This band migrated at a location that may correspond to the molecular weight of the TBC1D1 and TBC1D4 proteins. However, the PAS antibody does not distinguish between TBC1D1 and TBC1D4 phosphorylation. Thus, the relative contribution of these two proteins to the PAS signal can not be discerned using this antibody. To resolve this question, protein homogenates of gastrocnemius were immunoprecipitated using TBC1D1 and TBC1D4 antibodies. PAS levels in immunoprecipitate samples of TBC1D1 (Figure 4B and C, P = 0.048) and TBC1D4 (Figure 4B and D, P = 0.025) were lower in gastrocnemius of control ob/ob as compared to wild type animals. No statistically significant differences were observed for PAS-TBC1D1 and PAS-TBC1D4 protein levels between the control ob/ob and pair-fed ob/ob groups. Importantly, signals from PAS-TBC1D1 and PAS-TBC1D4 were substantially increased after leptin treatment as compared to control ob/ob (P = 0.015 and P = 0.023, respectively) and pair-fed ob/ob (P = 0.036 and P = 0.034, respectively) mice.
A: Representative phospho-Akt substrate (PAS) immunoblot of gastrocnemius lysate of wild type (WT), control ob/ob (OB), pair-fed ob/ob (PF) and leptin-treated ob/ob (LE) mice. The arrow indicates the band that may correspond to TBC1D1/4. B: Representative blots of immunoprecipitation and immunoblotting experiments. Equal amounts of protein (250 µg) from lysates of the gastrocnemius of WT, OB, PF and LE mice were incubated with TBC1D1 or TBC1D4 antibodies. Immunoprecipitated (IP) samples of TBC1D1 and TBC1D4 were resolved by SDS-PAGE and membranes were immunoblotted (WB) using PAS and GLUT4 antibodies. Membranes of immunoprecipitates probed with PAS and GLUT4 antibodies were stripped and re-probed with the corresponding total antibody TBC1D1 and TBC1D4. The signals from PAS-TBC1D1 and GLUT4-TBC1D1 and PAS-TBC1D4 and GLUT4-TBC1D4 were related to total TBC1D1 and TBC1D4, respectively (n = 6 per group). Leptin increases the phosphorylation levels of TBC1D1 (C) and TBC1D4 (D) in the gastrocnemius of leptin-treated ob/ob mice. GLUT4 co-precipitates with intracellular TBC1D1 (E) and TBC1D4 (F) proteins. Values are presented as means±SEM. * P<0.05 by one-way ANOVA followed by LSD tests.
Leptin reduces the immunocomplexes of TBC1D1 and TBC1D4 with GLUT4 in ob/ob mice
Since TBC1D1 and TBC1D4 proteins bind GLUT4 to block its translocation from intracellular storage compartments to the plasma membrane, we resolved GLUT4 from the immunoprecipitated samples of TBC1D1 and TBC1D4 in gastrocnemius muscle to examine whether GLUT4 co-precipitates with TBC1D1 and TBC1D4 proteins. As shown in Figure 4B and E-, GLUT4 signals detected in immunoprecipitated samples from TBC1D1 tended to be reduced by leptin treatment as compared to control ob/ob and pair-fed ob/ob mice, although statistically significant differences were not reached. A similar pattern was observed for GLUT4 in immunoprecipitated samples from TBC1D4, which was reduced in leptin-treated ob/ob as compared to control ob/ob (P = 0.013) and pair-fed ob/ob (P = 0.037) mice (Figure 4B and F). No statistical differences were detected between control ob/ob and pair-fed ob/ob groups for GLUT4 proteins in immunoprecipitated samples from TBC1D1 and TBC1D4.
Discussion
The purpose of our study was to examine the in vivo effects of leptin replacement on key molecules regulating GLUT4 translocation in skeletal muscle of the obese and diabetic ob/ob mice. Our findings show, for the first time, that leptin administration represses the increased transcript levels and activity of the negative regulators of GLUT4 traffic Tbc1d1 and Tbc1d4 in the gastrocnemius muscle of ob/ob mice.
Food intake restriction modulates insulin sensitivity and the expression of GLUT4 in human and rodent insulin sensitive tissues [23], [24]. Our data confirm that leptin significantly improves insulin sensitivity in ob/ob mice independently of the reduction in food intake. However, the effect of leptin on basal or insulin-stimulated glucose uptake in skeletal muscle has yielded many paradoxical observations [25]. No effect of leptin on glucose uptake was observed in human skeletal muscle cells [26], isolated mouse soleus [27] or rat epitrochlearis muscles [28]. In contrast, several in vitro studies have reported that leptin increases basal glucose uptake in C2C12 muscle cells [16] and in skeletal muscle of mice [29]. Furthermore, in vivo leptin treatment increases the glucose uptake in skeletal muscle [17] and improves the insulin sensitivity in normal [30] and diabetic rodents [15] as well as in leptin-deficient ob/ob mice [31].
Translocation of GLUT4 from intracellular depots to the plasma membrane of cells is key in glucose uptake, but GLUT4 traffic disruption in human type 2 diabetes has been described [2]. Several studies have examined the role of leptin on GLUT4 translocation showing controversial results. Acute treatment with leptin reduced insulin-stimulated glucose uptake without altering insulin-stimulated GLUT4 translocation in muscle cells of rats [32]. Furthermore, in the absence of insulin, high concentrations of leptin are unable to induce GLUT4 translocation in the soleus of rats [33]. Contrarily, leptin caused a small increase in glucose uptake and movement of GLUT4 to the plasma membrane in C2C12 muscle cells [16], [34]. In addition, chronic leptin treatment normalized basal glucose transport and GLUT4 content in soleus, but not in the gastrocnemius of high-fat-fed rats [35], as well as the insulin-stimulated GLUT4 content at the cell surface of myotubes without any reduction in total GLUT4 expression [36]. In the present study, GLUT4 mRNA expression was reduced by leptin deficiency in the EDL of control ob/ob mice, but it was not modified by leptin administration. In addition, no differences were detected for gene and protein expression levels of GLUT4 between wild type and ob/ob groups in gastrocnemius and soleus in spite of the normalization of serum glucose and insulin sensitivity induced by leptin replacement in leptin-treated ob/ob animals. A plausible explanation for this finding may relate to the leptin enhancement of GLUT4 activity by inhibiting the activity of TBC1D1 and TBC1D4 and via the alteration of the GLUT4 protein intracellular localization. In this sense, the activity of both TBC1D1 and TBC1D4 can be inhibited by phosphorylation by Akt and AMPK on PAS motif sites in response to insulin or contractile activity [37], [38], [39]. Impaired insulin-induced GLUT4 traffic and phosphorylation of TBC1D4 [40] are restored by endurance exercise-training in skeletal muscle of type 2 diabetes patients [41]. In addition, insulin-stimulated glucose transport and cell surface GLUT4 content are reduced in isolated muscles of mice with Tbc1d4-Thr649Ala knockin mutation, but not in adipocytes [42], while inhibition of Tbc1d4 in 3T3-L1 adipocytes increases the content of GLUT4 in the plasma membrane [43]. In contrast, knockdown of Tbc1d1 in 3T3-L1 adipocytes does not alter the insulin-stimulated GLUT4 translocation to the plasma membrane, whereas its overexpression partially inhibits the translocation of GLUT4 induced by AMPK [44]. A substantial body of evidence links the activation of AMPK with the reduction of the rate of GLUT4 endocytosis in skeletal muscle [45]. While Akt increases glucose uptake mainly through its action on TBC1D4, AMPK mediates it via the inhibition of TBC1D1 in skeletal muscle of rats [46]. More recently it has been reported that the catalytic AMPK-α2 is the main subunit of AMPK regulating TBC1D1-Ser237 phosphorylation in mice skeletal muscle [47], while disruption of AMPK-α1 signaling prevents the suppressive effects of AMPK activation on TBC1D4 phosphorylation [48]. In this sense, leptin activates AMPK in skeletal muscle [20], [21] and direct or indirect activation of AMPK stimulates the gene expression of GLUT4 [18], [49] and promotes its translocation to the sarcolemma [19]. In this regard, our microarray and real-time PCR data evidenced that administration of leptin suppresses the increased gene expression levels of Tbc1d1 and Tbc1d4 in ob/ob mice. In addition, leptin replacement enhanced the lower PAS-TBC1D1 and PAS-TBC1D4 protein levels in ob/ob mice, at the same time as reducing protein complexes of GLUT4 with TBC1D4. Therefore, given that the phosphorylation of TBC1D1 and TBC1D4 suppresses its GAP activity allowing for the translocation of GLUT4 vesicles to the plasma membrane, our findings indicate that leptin may inhibit the activity of TBC1D1 and TBC1D4 in the gastrocnemius of ob/ob mice. Noteworthy, a decrease of the expression of Tbc1d1 and Tbc1d4 in gastrocnemius muscle of pair fed ob/ob, thought to a lesser extent than in leptin-treated ob/ob, was determined. In this respect, given that weight loss has beneficial effects on skeletal muscle insulin sensitivity [23], [24], the possibility that weight loss may alter the TBC1D1 and TBC1D4 expression and/or phosphorylation in skeletal muscle independently of a direct leptin effect should be considered. However, PAS-TBC1D1 and PAS-TBC1D4 levels were increased after leptin administration in leptin-treated ob/ob as compared to control ob/ob and pair-fed ob/ob groups. In addition, several in vitro and in vivo studies have reported that expression and phosphorylation of TBC1D1 and TBC1D4 in skeletal muscle of rodents [24] and humans [50], [51] are not affected by diet intervention and weight loss. Furthermore, in a previous study, leptin administration did not modify body weight and total TBC1D4 protein expression in soleus of rats, but the hormone was able to recover the in vitro impaired insulin-stimulated phosphorylation of TBC1D4 induced by high-fat diet [52]. These studies suggest that modulations of the phosphorylation of TBC1D1 and TBC1D4 do not appear to be early components of the adaptation to weight loss. In this context, discerning whether the improved insulin sensitivity after leptin treatment is associated with an increased insulin-stimulated phosphorylation of TBC1D1 and/or TBC1D4 represents an important topic for future investigations.
In skeletal muscle, TG accumulation leads to insulin resistance. Circulating concentrations of FFA modulate the insulin sensitivity and GLUT4 expression in skeletal muscle with high intramyocellular content leading to insulin resistance [53]. In this sense, serum FFA were not modified by leptin deficiency or administration. In addition, although higher circulating concentrations of FFA and TG were detected in pair-fed ob/ob as compared to leptin-treated ob/ob mice, no differences for intramyocellular TG content were found. Data suggests an additional effect of leptin on the modulation of the expression and phosphorylation of TBC1D1 and TBC1D4 in ob/ob mice independently of the reduction of food intake and circulating concentrations of FFA and TG content in muscle cells.
Consistent with our results, GLUT4 gene and protein expression were not altered in skeletal muscle of insulin-resistant subjects [54] and in skeletal muscle of rats with increased insulin sensitivity after exercise [55], [56], or chronic leptin treatment [17], [57]. Regulation of glucose uptake has been shown to be fiber-type specific in skeletal muscle of rodents [58], [59]. In addition, a muscle-specific fiber-type expression of GLUT proteins has been reported in several studies [60], [61], [62]. To date, 14 members of the GLUT family have been identified, but 3 of them (GLUT4, GLUT5 and GLUT12) account for 98% of the mRNA in human skeletal muscle [62]. Stuart et al. [62] showed that GLUT3, GLUT4 and GLUT12 are predominantly expressed in slow-twitch oxidative fibers of human skeletal muscle. In contrast, the GLUT5 isoform was predominantly detected in fast-twitch glycolytic fibers. Moreover, GLUT12 has been recently identified as a potential candidate for a second insulin-responsive glucose transporter in muscle and fat [63] and a positive regulation of GLUT5 activity and expression by oral administration of leptin has been reported in jejunum of rodents [64]. In the present study, leptin treatment increased transcript levels of GLUT3 and GLUT12 in ob/ob animals. These data suggests that GLUT3 and GLUT12 may be key targets for leptin in skeletal muscle of ob/ob mice, thereby warranting further studies in this direction.
Paradoxically, leptin increased GLUT4 immunostaining in fiber sections of the glycolytic muscle EDL of leptin-treated ob/ob mice, without altering the total GLUT4 protein content by immunoblotting. In addittion, the hormone was unable to modify the GLUT4 staining pattern in the oxidative muscle soleus consistent with immunoblotting results. Controversial results about GLUT4 protein expression by different methods have been detected in several studies [65], [66], [67]. GLUT4 is expressed in different cell types in skeletal muscle tissue. In addition, both fiber-type-dependent and independent factors affect GLUT-4 expression [65], [68] and although EDL is a glycolytic muscle it is composed by different fiber types. Thus, the results on the expression of GLUT4 by immunoblotting and immunostaining in our study would probably be more in accordance performing immunoblotting experiments on single muscle fibers to avoid the influence of another cell type and discriminate the effect of the different fiber types. Furthermore, in the mixed muscle gastrocnemius, total GLUT4 protein content was not different between wild type and ob/ob groups, but the GLUT4 immunostaining pattern induced by leptin administration was almost exclusively relegated to some fibers, as compared to leptin-deficient mice (control ob/ob and pair-fed ob/ob groups), in which the staining pattern of GLUT4 was uniformly distributed among all the gastrocnemius fibers. Leptin appears to increase the GLUT4 signal preferably in some fibers rather than in all of them. Therefore, given that leptin administration was unable to modify the GLUT4 protein abundance in muscle but increased the GLUT4 signal in EDL sections, the lack of differences in GLUT4 protein abundance between groups may be explained by an increase in GLUT4 expression in glycolytic fibers masked by a decrease in the oxidative ones. Another possibility is that leptin alters the intracellular localization of GLUT4 in a fiber-type dependent manner in the gastrocnemius. Accordingly, we can not rule out the possibility that the lack of a leptin effect on GLUT4 mRNA and protein levels may be related to a fiber-type specific effect of the hormone, while warrants future studies for its elucidation.
Subsequently to GLUT4 translocation, a required point for glucose uptake is the fusion of GLUT4-containing vesicles to the plasma membrane. This process is mediated by SNARE proteins [8], [9]. In this sense, the present study shows, for the first time, that leptin administration up-regulates gene expression of proteins involved in the fusion of GLUT4-containing vesicles with the plasma membrane, such as Vamp2, Stx4 and Stxbp4 in the gastrocnemius of leptin-treated ob/ob mice. Leptin also enhanced the transcript levels of Sort1, which plays an essential role in the formation of GLUT4 storage vesicles in adipocytes [69] and muscle cells [70]. In addition, overexpression of sortilin in C2C12 cells enhances the insulin-induced glucose transport by increasing the gene expression levels of GLUT4 [70]. In accordance with our study, a recent report has further shown that mRNA levels of sortilin are down-regulated in adipose tissue and muscles of ob/ob and db/db mice as well as morbidly obese humans [71].
In summary, our findings provide new insights into the molecular mechanisms triggered by leptin in the regulation of glucose metabolism. Data suggests that leptin replacement improves the defective glucose homeostasis of ob/ob mice enhancing the presence of GLUT4 in the plasma membrane of the skeletal muscle cells by reducing the expression and increasing the phosphorylation of the negative regulators of GLUT4 translocation TBC1D1 and TBC1D4.
Acknowledgments
The authors would like to thank all the staff of the animal housing facilities for their technical expertise in animal care and handling and, in particular, to Javier Guillén, Elena Ciordia and Juan Percaz.
Author Contributions
Conceived and designed the experiments: NS JGA GF. Performed the experiments: NS AR VC SB BR AL EBR. Analyzed the data: NS AR VC JGA GF. Contributed reagents/materials/analysis tools: JGA GF. Wrote the paper: NS AR VC JGA GF.
References
- 1. Huang S, Czech MP (2007) The GLUT4 glucose transporter. Cell Metab 5: 237–252.
- 2. Maianu L, Keller SR, Garvey WT (2001) Adipocytes exhibit abnormal subcellular distribution and translocation of vesicles containing glucose transporter 4 and insulin-regulated aminopeptidase in type 2 diabetes mellitus: implications regarding defects in vesicle trafficking. J Clin Endocrinol Metab 86: 5450–5456.
- 3. Kane S, Sano H, Liu SC, Asara JM, Lane WS, et al. (2002) A method to identify serine kinase substrates. Akt phosphorylates a novel adipocyte protein with a Rab GTPase-activating protein (GAP) domain. J Biol Chem 277: 22115–22118.
- 4. Eguez L, Lee A, Chavez JA, Miinea CP, Kane S, et al. (2005) Full intracellular retention of GLUT4 requires AS160 Rab GTPase activating protein. Cell Metab 2: 263–272.
- 5. Taylor EB, An D, Kramer HF, Yu H, Fujii NL, et al. (2008) Discovery of TBC1D1 as an insulin-, AICAR-, and contraction-stimulated signaling nexus in mouse skeletal muscle. J Biol Chem 283: 9787–9796.
- 6. Chadt A, Leicht K, Deshmukh A, Jiang LQ, Scherneck S, et al. (2008) Tbc1d1 mutation in lean mouse strain confers leanness and protects from diet-induced obesity. Nat Genet 40: 1354–1359.
- 7. Sakamoto K, Holman GD (2008) Emerging role for AS160/TBC1D4 and TBC1D1 in the regulation of GLUT4 traffic. Am J Physiol Endocrinol Metab 295: E29–37.
- 8. Foster LJ, Klip A (2000) Mechanism and regulation of GLUT-4 vesicle fusion in muscle and fat cells. Am J Physiol Cell Physiol 279: C877–890.
- 9. Brandie FM, Aran V, Verma A, McNew JA, Bryant NJ, et al. (2008) Negative regulation of syntaxin4/SNAP-23/VAMP2-mediated membrane fusion by Munc18c in vitro. PLoS ONE 3: e4074.
- 10. Frühbeck G, Gómez-Ambrosi J (2001) Rationale for the existence of additional adipostatic hormones. FASEB J 15: 1996–2006.
- 11. Frühbeck G, Gómez-Ambrosi J (2003) Control of body weight: a physiologic and transgenic perspective. Diabetologia 46: 143–172.
- 12. Frühbeck G (2006) Intracellular signalling pathways activated by leptin. Biochem J 393: 7–20.
- 13. Anubhuti V, Arora S (2008) Leptin and its metabolic interactions - an update. Diab Obes Metab 10: 973–993.
- 14. Frühbeck G, Salvador J (2000) Relation between leptin and the regulation of glucose metabolism. Diabetologia 43: 3–12.
- 15. Ebihara K, Ogawa Y, Masuzaki H, Shintani M, Miyanaga F, et al. (2001) Transgenic overexpression of leptin rescues insulin resistance and diabetes in a mouse model of lipoatrophic diabetes. Diabetes 50: 1440–1448.
- 16. Berti L, Kellerer M, Capp E, Haring HU (1997) Leptin stimulates glucose transport and glycogen synthesis in C2C12 myotubes: evidence for a P13-kinase mediated effect. Diabetologia 40: 606–609.
- 17. Yaspelkis BB, Singh MK, Krisan AD, Collins DE, Kwong CC, et al. (2004) Chronic leptin treatment enhances insulin-stimulated glucose disposal in skeletal muscle of high-fat fed rodents. Life Sci 74: 1801–1816.
- 18. Holmes BF, Sparling DP, Olson AL, Winder WW, Dohm GL (2005) Regulation of muscle GLUT4 enhancer factor and myocyte enhancer factor 2 by AMP-activated protein kinase. Am J Physiol Endocrinol Metab 289: E1071–1076.
- 19. Kurth-Kraczek EJ, Hirshman MF, Goodyear LJ, Winder WW (1999) 5′ AMP-activated protein kinase activation causes GLUT4 translocation in skeletal muscle. Diabetes 48: 1667–1671.
- 20. Minokoshi Y, Kim YB, Peroni OD, Fryer LG, Muller C, et al. (2002) Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 415: 339–343.
- 21. Sáinz N, Rodríguez A, Catalán V, Becerril S, Ramírez B, et al. (2009) Leptin administration favors muscle mass accretion by decreasing FoxO3a and increasing PGC-1α in ob/ob mice. PLoS ONE 4: e6808.
- 22. Wieland O (1957) Enzymatic method for the determination of glycerin. Biochem Z 329: 313–319.
- 23. Alonso A, Fernández Y, Fernández R, Ordoñez P, Moreno M, et al. (2005) Effect of food restriction on the insulin signalling pathway in rat skeletal muscle and adipose tissue. J Nutr Biochem 16: 602–609.
- 24. Sharma N, Arias EB, Bhat AD, Sequea DA, Ho S, et al. (2011) Mechanisms for increased insulin-stimulated Akt phosphorylation and glucose uptake in fast- and slow-twitch skeletal muscles of calorie-restricted rats. Am J Physiol Endocrinol Metab 300: E966–978.
- 25. Ceddia R, Koistinen H, Zierath J, Sweeney G (2002) Analysis of paradoxical observations on the association between leptin and insulin resistance. FASEB J 16: 1163–1176.
- 26. Ranganathan S, Ciaraldi TP, Henry RR, Mudaliar S, Kern PA (1998) Lack of effect of leptin on glucose transport, lipoprotein lipase, and insulin action in adipose and muscle cells. Endocrinology 139: 2509–2513.
- 27. Zierath JR, Frevert EU, Ryder JW, Berggren PO, Kahn BB (1998) Evidence against a direct effect of leptin on glucose transport in skeletal muscle and adipocytes. Diabetes 47: 1–4.
- 28. Furnsinn C, Brunmair B, Furtmuller R, Roden M, Englisch R, et al. (1998) Failure of leptin to affect basal and insulin-stimulated glucose metabolism of rat skeletal muscle in vitro. Diabetologia 41: 524–529.
- 29. Ceddia R, William WJ, Curi R (1999) Comparing effects of leptin and insulin on glucose metabolism in skeletal muscle: evidence for an effect of leptin on glucose uptake and decarboxylation. Int J Obes Relat Metab Disord 23: 75–82.
- 30. Kamohara S, Burcelin R, Halaas JL, Friedman JM, Charron MJ (1997) Acute stimulation of glucose metabolism in mice by leptin treatment. Nature 389: 374–377.
- 31. Muzzin P, Eisensmith RC, Copeland KC, Woo SL (1996) Correction of obesity and diabetes in genetically obese mice by leptin gene therapy. Proc Natl Acad Sci USA 93: 14804–14808.
- 32. Sweeney G, Keen J, Somwar R, Konrad D, Garg R, et al. (2001) High leptin levels acutely inhibit insulin-stimulated glucose uptake without affecting glucose transporter 4 translocation in l6 rat skeletal muscle cells. Endocrinology 142: 4806–4812.
- 33. Alkhateeb H, Chabowski A, Glatz JF, Gurd B, Luiken JJ, et al. (2009) Restoring AS160 phosphorylation rescues skeletal muscle insulin resistance and fatty acid oxidation while not reducing intramuscular lipids. Am J Physiol Endocrinol Metab 297: E1056–E1066.
- 34. Berti L, Gammeltoft S (1999) Leptin stimulates glucose uptake in C2C12 muscle cells by activation of ERK2. Mol Cell Endocrinol 157: 121–130.
- 35. Yaspelkis BB, Saberi M, Singh MK, Trevino B, Smith TL (2002) Chronic leptin treatment normalizes basal glucose transport in a fiber type-specific manner in high-fat-fed rats. Metabolism 51: 859–863.
- 36. Tajmir P, Kwan JJ, Kessas M, Mozammel S, Sweeney G (2003) Acute and chronic leptin treatment mediate contrasting effects on signaling, glucose uptake, and GLUT4 translocation in L6-GLUT4myc myotubes. J Cell Physiol 197: 122–130.
- 37. Sano H, Kane S, Sano E, Miinea CP, Asara JM, et al. (2003) Insulin-stimulated phosphorylation of a Rab GTPase-activating protein regulates GLUT4 translocation. J Biol Chem 278: 14599–14602.
- 38. Bruss MD, Arias EB, Lienhard GE, Cartee GD (2005) Increased phosphorylation of Akt substrate of 160 kDa (AS160) in rat skeletal muscle in response to insulin or contractile activity. Diabetes 54: 41–50.
- 39. Kramer HF, Witczak CA, Taylor EB, Fujii N, Hirshman MF, et al. (2006) AS160 regulates insulin- and contraction-stimulated glucose uptake in mouse skeletal muscle. J Biol Chem 281: 31478–31485.
- 40. Karlsson HK, Zierath JR, Kane S, Krook A, Lienhard GE, et al. (2005) Insulin-stimulated phosphorylation of the Akt substrate AS160 is impaired in skeletal muscle of type 2 diabetic subjects. Diabetes 54: 1692–1697.
- 41. Vind BF, Pehmoller C, Treebak JT, Birk JB, Hey-Mogensen M, et al. (2011) Impaired insulin-induced site-specific phosphorylation of TBC1 domain family, member 4 (TBC1D4) in skeletal muscle of type 2 diabetes patients is restored by endurance exercise-training. Diabetologia 54: 157–167.
- 42. Chen S, Wasserman DH, MacKintosh C, Sakamoto K (2011) Mice with AS160/TBC1D4-Thr649Ala knockin mutation are glucose intolerant with reduced insulin sensitivity and altered GLUT4 trafficking. Cell Metab 13: 68–79.
- 43. Larance M, Ramm G, Stockli J, van Dam EM, Winata S, et al. (2005) Characterization of the role of the Rab GTPase-activating protein AS160 in insulin-regulated GLUT4 trafficking. J Biol Chem 280: 37803–37813.
- 44. Chavez JA, Roach WG, Keller SR, Lane WS, Lienhard GE (2008) Inhibition of GLUT4 translocation by Tbc1d1, a Rab GTPase-activating protein abundant in skeletal muscle, is partially relieved by AMP-activated protein kinase activation. J Biol Chem 283: 9187–9195.
- 45. Karlsson HK, Chibalin AV, Koistinen HA, Yang J, Koumanov F, et al. (2009) Kinetics of GLUT4 trafficking in rat and human skeletal muscle. Diabetes 58: 847–854.
- 46. Funai K, Cartee GD (2009) Inhibition of contraction-stimulated AMP-activated protein kinase inhibits contraction-stimulated increases in PAS-TBC1D1 and glucose transport without altering PAS-AS160 in rat skeletal muscle. Diabetes 58: 1096–1104.
- 47. Frosig C, Pehmoller C, Birk JB, Richter EA, Wojtaszewski JF (2010) Exercise-induced TBC1D1 Ser237 phosphorylation and 14-3-3 protein binding capacity in human skeletal muscle. J Physiol 588: 4539–4548.
- 48. Gaidhu MP, Perry RL, Noor F, Ceddia RB (2010) Disruption of AMPKalpha1 signaling prevents AICAR-induced inhibition of AS160/TBC1D4 phosphorylation and glucose uptake in primary rat adipocytes. Mol Endocrinol 24: 1434–1440.
- 49. Jessen N, Pold R, Buhl ES, Jensen LS, Schmitz O, et al. (2003) Effects of AICAR and exercise on insulin-stimulated glucose uptake, signaling, and GLUT-4 content in rat muscles. J Appl Physiol 94: 1373–1379.
- 50. Jessen N, An D, Lihn AS, Nygren J, Hirshman MF, et al. (2011) Exercise increases TBC1D1 phosphorylation in human skeletal muscle. Am J Physiol Endocrinol Metab 301: E164–171.
- 51. Breen L, Philp A, Shaw CS, Jeukendrup AE, Baar K, et al. (2011) Beneficial effects of resistance exercise on glycemic control are not further improved by protein ingestion. PLoS ONE 6: e20613.
- 52. Stefanyk LE, Gulli RA, Ritchie IR, Chabowski A, Snook LA, et al. (2011) Recovered insulin response by 2 weeks of leptin administration in high-fat fed rats is associated with restored AS160 activation and decreased reactive lipid accumulation. Am J Physiol Regul Integr Comp Physiol 301: R159–171.
- 53. Manco M, Calvani M, Mingrone G (2004) Effects of dietary fatty acids on insulin sensitivity and secretion. Diab Obes Metab 6: 402–413.
- 54. Stuart CA, Wen G, Williamson ME, Jiang J, Gilkison CR, et al. (2001) Altered GLUT1 and GLUT3 gene expression and subcellular redistribution of GLUT4: protein in muscle from patients with acanthosis nigricans and severe insulin resistance. Metabolism 50: 771–777.
- 55. Cheng IS, Lee NY, Liu KL, Liao SF, Huang CH, et al. (2005) Effect of postexercise carbohydrate supplementation on glucose uptake-associated gene expression in the human skeletal muscle. J Nutr Biochem 16: 267–271.
- 56. Funai K, Schweitzer GG, Sharma N, Kanzaki M, Cartee GD (2009) Increased AS160 phosphorylation, but not TBC1D1 phosphorylation, with increased postexercise insulin sensitivity in rat skeletal muscle. Am J Physiol Endocrinol Metab 297: E242–251.
- 57. Wang JL, Chinookoswong N, Scully S, Qi M, Shi ZQ (1999) Differential effects of leptin in regulation of tissue glucose utilization in vivo. Endocrinology 140: 2117–2124.
- 58. Wright DC, Hucker KA, Holloszy JO, Han DH (2004) Ca2+ and AMPK both mediate stimulation of glucose transport by muscle contractions. Diabetes 53: 330–335.
- 59. Wright DC, Geiger PC, Holloszy JO, Han DH (2005) Contraction- and hypoxia-stimulated glucose transport is mediated by a Ca2+-dependent mechanism in slow-twitch rat soleus muscle. Am J Physiol Endocrinol Metab 288: E1062–1066.
- 60. Marette A, Richardson JM, Ramlal T, Balon TW, Vranic M, et al. (1992) Abundance, localization, and insulin-induced translocation of glucose transporters in red and white muscle. Am J Physiol 263: C443–452.
- 61. Stuart CA, Wen G, Peng BH, Popov VL, Hudnall SD, et al. (2000) GLUT-3 expression in human skeletal muscle. Am J Physiol Endocrinol Metab 279: E855–861.
- 62. Stuart CA, Yin D, Howell ME, Dykes RJ, Laffan JJ, et al. (2006) Hexose transporter mRNAs for GLUT4, GLUT5, and GLUT12 predominate in human muscle. Am J Physiol Endocrinol Metab 291: E1067–1073.
- 63. Stuart CA, Howell ME, Zhang Y, Yin D (2009) Insulin-stimulated translocation of glucose transporter (GLUT) 12 parallels that of GLUT4 in normal muscle. J Clin Endocrinol Metab 94: 3535–3542.
- 64. Sakar Y, Nazaret C, Letteron P, Ait Omar A, Avenati M, et al. (2009) Positive regulatory control loop between gut leptin and intestinal GLUT2/GLUT5 transporters links to hepatic metabolic functions in rodents. PLoS ONE 4: e7935.
- 65. Gaster M, Poulsen P, Handberg A, Schroder HD, Beck-Nielsen H (2000) Direct evidence of fiber type-dependent GLUT-4 expression in human skeletal muscle. Am J Physiol Endocrinol Metab 278: E910–916.
- 66. Gaster M, Staehr P, Beck-Nielsen H, Schroder HD, Handberg A (2001) GLUT4 is reduced in slow muscle fibers of type 2 diabetic patients: is insulin resistance in type 2 diabetes a slow, type 1 fiber disease? Diabetes 50: 1324–1329.
- 67. Benomar Y, Naour N, Aubourg A, Bailleux V, Gertler A, et al. (2006) Insulin and leptin induce Glut4 plasma membrane translocation and glucose uptake in a human neuronal cell line by a phosphatidylinositol 3-kinase- dependent mechanism. Endocrinology 147: 2550–2556.
- 68. Borghouts LB, Schaart G, Hesselink MK, Keizer HA (2000) GLUT-4 expression is not consistently higher in type-1 than in type-2 fibres of rat and human vastus lateralis muscles; an immunohistochemical study. Pflugers Arch 441: 351–358.
- 69. Shi J, Kandror KV (2005) Sortilin is essential and sufficient for the formation of Glut4 storage vesicles in 3T3-L1 adipocytes. Dev Cell 9: 99–108.
- 70. Ariga M, Nedachi T, Katagiri H, Kanzaki M (2008) Functional role of sortilin in myogenesis and development of insulin-responsive glucose transport system in C2C12 myocytes. J Biol Chem 283: 10208–10220.
- 71. Kaddai V, Jager J, González T, Najem-Lendom R, Bonnafous S, et al. (2009) Involvement of TNF-α in abnormal adipocyte and muscle sortilin expression in obese mice and humans. Diabetologia 52: 932–940.